INDICATIONS AND USAGE:Crizotinib is a kinase inhibitor indicated for the treatment of •Patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1 • Positive as detected by an FDA-approved test. Pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive • Limitations of Use: The safety and efficacy of Crizotinib have not been established in older adults with relapsed or refractory systemic ALK-positive ALCL 

DOSAGE AND ADMINISTRATION: Patient Selection Select patients for the treatment of metastatic NSCLC with Crizotinib based on the presence of ALK or ROS1 positivity in tumor specimens. Recommended Dosage for ALK- or ROS1-Positive Metastatic Non-Small Cell Lung Cancer The recommended dosage of Crizotinib for patients with NSCLC is 250 mg orally twice daily, with or without food, until disease progression or no longer tolerated by the patient.

FIND A PRODUCT